Dolby Laboratories, Inc. vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Dolby Laboratories, Inc. trades at $58.65 (market cap $5.47B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.49 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 4.6× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays the higher dividend (2.46%). Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| DLB | RPRX | |
|---|---|---|
Market Cap | $5.47B | $25.27B |
Volume | 1,058,284 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $70.09 | $63.96 |
52-Week Low | $48.51 | $35.44 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $4.85B | $32.50B |
Dividend Yield | 2.46% | 1.66% |
Signals from Pluang's Aura AI — not financial advice
DLB trades at $58.90, up 0.94% with bearish technical signals but strong fundamentals including 87.61% gross margins and consistent earnings beats. Recent expansion with Meta and leadership transition to Marc Whitten highlight growth initiatives. Cash flow improved significantly to $215.61M in 2025 from negative trends.
Analyst consensus targets $90.33 (53% upside) with 47% buy ratings, though technical indicators signal caution. Key risks include licensing volatility and execution during leadership change. Revenue stability and premium valuation at 24.87 P/E support long-term case if growth accelerates.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →